Press release
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Clinical Development Landscape 2025: Approvals, Trials, Mechanisms, and Pipeline Outlook by DelveInsight
Paroxysmal Nocturnal Hemoglobinuria Pipeline
According to DelveInsight's latest assessment, the PNH drug development ecosystem includes 20+ active pharmaceutical companies advancing 25+ therapeutic candidates across various clinical stages. The report provides granular insights into clinical trials, mechanisms of action, routes of administration, and product-specific advances across the entire developmental pipeline.
Download free sample report @ Paroxysmal Nocturnal Hemoglobinuria Pipeline Outlook - https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Paroxysmal Nocturnal Hemoglobinuria Active Innovators and Market Participants
A broad and diverse group of biopharma companies continue to advance novel therapies for Paroxysmal Nocturnal Hemoglobinuria.
Leading Paroxysmal Nocturnal Hemoglobinuria companies include:
• Hoffmann-La Roche (Chugai Pharmaceutical)
• AstraZeneca (Alexion Pharmaceuticals)
• Apellis Pharmaceuticals
• Swedish Orphan Biovitrum
• Regeneron Pharmaceuticals
• Alnylam Pharmaceuticals
• Omeros Corporation
• BioCryst Pharmaceuticals
• Novartis
• Chengdu Suncadia Medicine
• Wuhan Createrna Science
• Kira Pharma
• NovelMed Therapeutics, and others.
These organizations collectively represent the forefront of innovation in complement inhibition, oral therapeutics, monoclonal antibodies, and next-generation Paroxysmal Nocturnal Hemoglobinuria treatment modalities.
Download sample report to know in detail about Paroxysmal Nocturnal Hemoglobinuria therapies @ Paroxysmal Nocturnal Hemoglobinuria Pipeline Outlook - https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Paroxysmal Nocturnal Hemoglobinuria Emerging Therapies Expected to Transform the Market
Therapies under clinical investigation include several high-impact candidates such as:
• PIASKY (Crovalimab) - Hoffmann-La Roche
• SOLIRIS (Eculizumab) - AstraZeneca
• EMPAVELI/ASPAVELI (Pegcetacoplan) - Apellis/SOBI
• Pozelimab (REGN3918) - Regeneron/Alnylam
• Zaltenibart (OMS906) - Omeros
• Iptacopan (Fabhalta) - Novartis
• BCX9930 - BioCryst
• KP104 - Kira Pharma
• NM8074 - NovelMed
• Danicopan - Alexion Pharmaceuticals
These candidates are demonstrating strong therapeutic potential across Phase I-III trials, with several expected to shift treatment paradigms in the coming years.
Paroxysmal Nocturnal Hemoglobinuria Key Clinical and Regulatory Milestones (2024-2025)
Novartis (June 2025)
The company released favorable results from the Phase 3B APPULSE-PNH trial evaluating iptacopan, a twice-daily oral monotherapy, in patients transitioned from anti-C5 therapies such as eculizumab and ravulizumab.
Regeneron Pharmaceuticals (June 2025)
Regeneron shared long-term findings from an Open-Label Extension investigating the combination of pozelimab + cemdisiran, demonstrating encouraging safety and efficacy outcomes.
Chugai Pharmaceutical (May 2025)
Chugai Pharma Taiwan received Taiwan FDA orphan drug import approval for PiaSky® (crovalimab) for patients aged ≥13 years and weighing ≥40 kg.
NovelMed Therapeutics (May 2025)
NovelMed reported promising 12-week interim Phase II results for Ruxoprubart, highlighting improved hemoglobin, reduced LDH, transfusion independence, and significant symptom control.
Omeros Corporation (December 2024)
Presentations at ASH 2024 highlighted positive Phase II data for zaltenibart (OMS906) with Phase III trial initiation planned for early 2025.
Paroxysmal Nocturnal Hemoglobinuria Regulatory Approvals
• EMA (Aug 2024): Approved PIASKY (crovalimab) for adults/adolescents ≥12 years.
• FDA (Jun 2024): Approved crovalimab for adults and pediatric patients ≥13 years.
Get a Free Sample PDF Report to know more about Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Paroxysmal Nocturnal Hemoglobinuria Disease Overview
Paroxysmal Nocturnal Hemoglobinuria is a rare, acquired hematologic disorder driven by PIGA gene mutations, resulting in absent GPI-anchored proteins (especially CD55/CD59) and uncontrolled complement-mediated hemolysis. Clinical manifestations include:
• Chronic intravascular hemolysis
• Pancytopenia
• Thrombotic events
• Dark urine, fatigue, abdominal pain
• Complications: kidney dysfunction, pulmonary hypertension, stroke
Paroxysmal Nocturnal Hemoglobinuria Diagnosis primarily relies on flow cytometry, and modern treatments focus on complement inhibition, with eculizumab and ravulizumab being standard therapies. Investigational agents are now targeting multiple pathways, including proximal complement blockade and oral factor inhibitors.
Further Paroxysmal Nocturnal Hemoglobinuria product details are provided in the report. Download the Paroxysmal Nocturnal Hemoglobinuria pipeline report to learn more about the emerging Paroxysmal Nocturnal Hemoglobinuria therapies - https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Paroxysmal Nocturnal Hemoglobinuria Pipeline Categorization
By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
By Molecule Type
• Monoclonal antibodies
• Peptides
• Small molecules
• Polymers
• Gene therapy
By Clinical Stage
• Phase III
• Phase II
• Phase I
• Preclinical & Discovery
• Discontinued/Inactive candidates
Paroxysmal Nocturnal Hemoglobinuria Market Dynamics and Trends
Paroxysmal Nocturnal Hemoglobinuria Market Drivers
• Rapid evolution of complement-targeted therapies
• Expanding therapeutic classes and mechanisms
• Growing geriatric population diagnosed with PNH
• Increased adoption of advanced biologics and oral agents
Paroxysmal Nocturnal Hemoglobinuria Market Barriers
• High therapeutic costs
• Reimbursement challenges
• Accessibility limitations in certain geographies
Download Sample PDF Report to know more about Paroxysmal Nocturnal Hemoglobinuria drugs and therapies - https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Paroxysmal Nocturnal Hemoglobinuria Pipeline Analyses Included in the Report
The DelveInsight report delivers:
• Detailed individual drug profiles
• Clinical trial timelines and outcomes
• Mechanism of action and pharmacological insights
• Collaboration networks, licensing deals, and funding updates
• Comparative analysis across therapy classes
• University-industry partnerships
• Assessment of unmet needs and future market outlook
The analysis relies on robust data from proprietary databases, clinical trial registries, regulatory filings, scientific conferences, and corporate disclosures.
Scope of Paroxysmal Nocturnal Hemoglobinuria Pipeline Drug Insight
• Coverage: Global
• Key Paroxysmal Nocturnal Hemoglobinuria Companies: Hoffmann-La Roche (Chugai Pharmaceutical), AstraZeneca (Alexion Pharmaceuticals), Apellis Pharmaceuticals, Swedish Orphan Biovitrum, Regeneron, Pharmaceuticals, Alnylam Pharmaceuticals, Omeros Corporation, BioCryst Pharmaceuticals, Novartis, Chengdu Suncadia Medicine Co., Ltd., Wuhan Createrna Science, Regeneron Pharma, Kira Pharma, NovelMed Therapeutics, and others
• Key Paroxysmal Nocturnal Hemoglobinuria Therapies: PIASKY (Crovalimab), SOLIRIS (eculizumab), EMPAVELI/ASPAVELI (pegcetacoplan), Pozelimab (REGN3918), Zaltenibart (OMS906), Eculizumab, BCX9930, Pegcetacoplan, Crovalimab, OMS906 study drug, HRS-5965 tablets, MY008211A tablets, Iptacopan, Pozelimab, KP104, NM8074, Danicopan, Pegcetacoplan, and others
• Paroxysmal Nocturnal Hemoglobinuria Therapeutic Assessment: Paroxysmal Nocturnal Hemoglobinuria current marketed and Paroxysmal Nocturnal Hemoglobinuria emerging therapies
• Paroxysmal Nocturnal Hemoglobinuria Market Dynamics: Paroxysmal Nocturnal Hemoglobinuria market drivers and Paroxysmal Nocturnal Hemoglobinuria market barriers
Request for Sample PDF Report for Paroxysmal Nocturnal Hemoglobinuria Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Paroxysmal Nocturnal Hemoglobinuria Report Introduction
2. Paroxysmal Nocturnal Hemoglobinuria Executive Summary
3. Paroxysmal Nocturnal Hemoglobinuria Overview
4. Paroxysmal Nocturnal Hemoglobinuria- Analytical Perspective In-depth Commercial Assessment
5. Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapeutics
6. Paroxysmal Nocturnal Hemoglobinuria Late Stage Products (Phase II/III)
7. Paroxysmal Nocturnal Hemoglobinuria Mid Stage Products (Phase II)
8. Paroxysmal Nocturnal Hemoglobinuria Early Stage Products (Phase I)
9. Paroxysmal Nocturnal Hemoglobinuria Preclinical Stage Products
10. Paroxysmal Nocturnal Hemoglobinuria Therapeutics Assessment
11. Paroxysmal Nocturnal Hemoglobinuria Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Paroxysmal Nocturnal Hemoglobinuria Key Companies
14. Paroxysmal Nocturnal Hemoglobinuria Key Products
15. Paroxysmal Nocturnal Hemoglobinuria Unmet Needs
16 . Paroxysmal Nocturnal Hemoglobinuria Market Drivers and Barriers
17. Paroxysmal Nocturnal Hemoglobinuria Future Perspectives and Conclusion
18. Paroxysmal Nocturnal Hemoglobinuria Analyst Views
19. Appendix
20. About DelveInsight
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Clinical Development Landscape 2025: Approvals, Trials, Mechanisms, and Pipeline Outlook by DelveInsight here
News-ID: 4290495 • Views: …
More Releases from DelveInsight Business Research
Inflammatory Breast Cancer Treatment Market Outlook 2032: Regulatory Milestones, …
Key Inflammatory Breast Cancer Contributors: Merck, AstraZeneca, Gilead Sciences, Daiichi Sankyo, Pfizer, among others.
Albany, USA - DelveInsight has released its latest study, "Inflammatory Breast Cancer Market Insights, Epidemiology, and Market Forecast - 2032," offering an extensive evaluation of the rapidly evolving landscape of Inflammatory Breast Cancer (IBC). The report provides strategic insights into historical and projected epidemiology, current treatment dynamics, emerging therapies, regulatory developments, and market performance across the United…
Uterine Serous Carcinoma Treatment Market Poised for Robust Expansion Across the …
Key Industry Leaders Include Pfizer, AstraZeneca, Elder Pharma, Merck & Co., Novartis, United Biotech, R-Pharm-US, Par Pharmaceutical, and Others
DelveInsight has released its latest publication, "Uterine Serous Carcinoma Market Insights, Epidemiology, and Market Forecast - 2032," offering a comprehensive assessment of the disease landscape, epidemiology, and evolving treatment dynamics across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Access the complete analysis and future outlook for…
Paranasal Sinus Cancer Treatment Market Poised for Steady Growth Across 7MM by 2 …
DelveInsight announces the release of its latest study, "Paranasal Sinus Cancer Market Insights, Epidemiology, and Market Forecast - 2032," offering a comprehensive evaluation of disease trends, therapeutic developments, and market dynamics across the United States, the five major European markets (Germany, France, Italy, Spain, and the UK), and Japan.
Gain an in-depth understanding of market forecasts, therapeutic innovations, and epidemiological insights by accessing the complete report here: Paranasal Sinus Cancer Therapeutics…
Global Digital Wound Measurement Devices Market Demonstrates Robust Growth Outlo …
The global Digital Wound Measurement Devices Market is entering a phase of sustained expansion, driven by rising clinical demand for precise wound assessment technologies, the growing prevalence of chronic and non-healing wounds, and the accelerated adoption of digital health and telemedicine platforms. According to recent market analysis, the sector is projected to increase from USD 370.51 million in 2024 to USD 565.83 million by 2032, reflecting a CAGR of 5.50%…
More Releases for Paroxysmal
Paroxysmal Nocturnal Hemoglobinuria Market Analysis , Trends, and Commercial Out …
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by the destruction of red blood cells (hemolysis), bone marrow failure, and a heightened risk of thrombosis. The disease significantly impacts patient quality of life, making early diagnosis and effective therapeutic management essential. With increasing awareness, improved diagnostic capabilities, and the development of targeted therapies, the PNH market is poised for considerable growth over the next decade.
Download Full PDF…
Major Market Shift in Paroxysmal Nocturnal Hemoglobinuria (PNH) Industry: Innova …
What Is the Forecasted Market Size and Growth Rate for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?
The paroxysmal nocturnal hemoglobinuria (PNH) market has grown rapidly in recent years. It will rise from $4.24 billion in 2024 to $4.68 billion in 2025, at a CAGR of 10.4%. This growth is due to the rising demand for treatments for PNH, increasing disposable incomes, government initiatives, and rising healthcare spending.
The paroxysmal nocturnal hemoglobinuria (PNH)…
Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapeutics Assessmsent Report 202 …
DelveInsight's, "Paroxysmal Nocturnal Haemoglobinuria Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Paroxysmal Nocturnal Haemoglobinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Paroxysmal Nocturnal Hemoglobinuria…
Paroxysmal Nocturnal Hemoglobinuria Market Insights, Forecast to 2031
Paroxysmal Nocturnal Hemoglobinuria Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Paroxysmal Nocturnal Hemoglobinuria industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a…
Paroxysmal Nocturnal Haemoglobinuria Pipeline Featuring 20+ Companies Expected t …
"The principal studies used to establish the diagnosis of PNH are flow cytometry of peripheral blood and bone marrow analysis. Paroxysmal Nocturnal Haemoglobinuria typically starts from the early thirties to the mid‐forties, and often persisting for decades, with a continued dependence on blood transfusions in a proportion of patients". The drug is described in detail in the Paroxysmal Nocturnal Haemoglobinuria pipeline report, along with its mechanism of action, Paroxysmal Nocturnal…
Paroxysmal Nocturnal Hemoglobinuria Market Report 2020-2030
Forecasts by Treatment (Medication, Stem Cell Transplant, Blood Transfusion) Plus Analysis of Leading Companies
Download free sample pages: https://www.visiongain.com/report/paroxysmal-nocturnal-hemoglobinuria-market-report-2020-2030/
Paroxysmal Nocturnal Hemoglobinuria Market- our new study reveals trends, R&D progress, and predicted revenues
Where the Paroxysmal Nocturnal Hemoglobinuria is market heading? If you are involved in this industry you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects…
